Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03143374 · ClinicalTrials.gov registry record · Phase 2
PET Tau - Neurodegenerative Disease Imaging
A Phase 2 study of Neuro-Degenerative Disease, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT03143374: Recruiting Phase 2 study of Neuro-Degenerative Disease, sponsored by University of Pennsylvania.
NCT03143374 is a Phase 2 study of Neuro-Degenerative Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 300 participants, below the 715-participant average among 11 other Neuro-Degenerative Disease trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03143374, a Phase 2 study of Neuro-Degenerative Disease, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).
Primary Outcome
Examine regional anatomic distribution of PET-tau uptake comparatively in dementia syndromes and PET-Tau uptake with neuropsychology and MRI regional GM atrophy at baseline collected under other center protocols. Uptake with neuropsychology and MRI regional GM atrophy at baseline.
Conditions Studied
Interventions
- DRUG 18F-AV-1451
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2016-08-23 |
| Est. Completion | 2030-09 |
| Phase | Phase 2 |
What NCT03143374 shows while recruiting
NCT03143374 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 715-participant average among 11 other Neuro-Degenerative Disease trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Neuro-Degenerative Disease appearing as the primary indexed condition, and to 1 intervention - of which 18F-AV-1451 is the first listed.
NCT03143374 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03143374 about?
NCT03143374 is a clinical study titled "PET Tau - Neurodegenerative Disease Imaging". The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such ...
What is the current status of trial NCT03143374?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2016-08-23. Estimated completion is 2030-09.
What conditions does trial NCT03143374 study?
This clinical trial studies the following conditions: Neuro-Degenerative Disease.
What interventions are being tested in trial NCT03143374?
The interventions under investigation include: 18F-AV-1451 (DRUG).
Who is sponsoring clinical trial NCT03143374?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03143374 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuro-Degenerative Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03143374's enrollment target sits among peer trials
300 4th of 11 higher than 8 of 11 other Neuro-Degenerative Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuro-Degenerative Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J
RECRUITING
-
Persons With Dementia and Their Extended Family Caregivers
RECRUITING
-
The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
RECRUITING
-
Mindfulness Walking Intervention to Enhance Resilience (iWalk)
RECRUITING · NA
-
FA Clinical Outcome Measures
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI